NeoPharm CO. LTD Cash Flow Conversion Efficiency

Latest as of September 2025: 0.031x

NeoPharm CO. LTD cash flow conversion efficiency. Based on the latest financial reports, NeoPharm CO. LTD (092730) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩5.88 Billion ≈ $3.98 Million USD) by net assets (₩188.40 Billion ≈ $127.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of NeoPharm CO. LTD (2012–2024)

Cash flow conversion efficiency of NeoPharm CO. LTD from 2012 to 2024. This chart illustrates how NeoPharm CO. LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NeoPharm CO. LTD (092730) stock price for real-time trading data and today's change.

NeoPharm CO. LTD Cash Flow Conversion Ratio Explained

NeoPharm CO. LTD cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

NeoPharm CO. LTD Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NeoPharm CO. LTD ranked by their cash flow conversion efficiency. Also see market value of NeoPharm CO. LTD for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Innate Pharma NASDAQ:IPHA	1.078x
KANGWON Co. Ltd KQ:114190	0.077x
Neo Technical System Co. Ltd KQ:085910	0.035x
Grupo Clarin S.A. BA:GCLA	-0.134x
Ally Leasehold Real Estate Investment Trust BK:ALLY	0.051x
MC Mining Ltd AU:MCM	-0.090x
Aurskog Sparebank OL:AURG	0.070x
E KOCREF CR REIT KO:088260	N/A

Annual Cash Flow Conversion Efficiency for NeoPharm CO. LTD (2012–2024)

The table below shows the annual cash flow conversion efficiency of NeoPharm CO. LTD from 2012 to 2024. Review NeoPharm CO. LTD free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩176.88 Billion ≈ $119.87 Million	₩18.63 Billion ≈ $12.63 Million	0.105x	-27.54%
2023-12-31	₩160.03 Billion ≈ $108.45 Million	₩23.26 Billion ≈ $15.76 Million	0.145x	+13.83%
2022-12-31	₩142.21 Billion ≈ $96.37 Million	₩18.16 Billion ≈ $12.31 Million	0.128x	-23.25%
2021-12-31	₩130.30 Billion ≈ $88.31 Million	₩21.68 Billion ≈ $14.69 Million	0.166x	+14.72%
2020-12-31	₩117.72 Billion ≈ $79.78 Million	₩17.07 Billion ≈ $11.57 Million	0.145x	-20.26%
2019-12-31	₩105.69 Billion ≈ $71.63 Million	₩19.22 Billion ≈ $13.03 Million	0.182x	-33.35%
2018-12-31	₩59.29 Billion ≈ $40.18 Million	₩16.18 Billion ≈ $10.96 Million	0.273x	+21.97%
2017-12-31	₩47.58 Billion ≈ $32.25 Million	₩10.65 Billion ≈ $7.21 Million	0.224x	-5.75%
2016-12-31	₩38.57 Billion ≈ $26.14 Million	₩9.16 Billion ≈ $6.21 Million	0.237x	+27.07%
2015-12-31	₩32.62 Billion ≈ $22.11 Million	₩6.09 Billion ≈ $4.13 Million	0.187x	+890.58%
2012-12-31	₩29.92 Billion ≈ $20.28 Million	₩564.34 Million ≈ $382.45K	0.019x	--

About NeoPharm CO. LTD

KQ:092730 Korea Personal & Household Products & Services

Market Cap

$124.79 Million

₩184.14 Billion KRW

Market Cap Rank

#18160 Global

#791 in Korea

Share Price

₩23050.00

Change (1 day)

+2.90%

52-Week Range

₩15760.00 - ₩25450.00

All Time High

₩27383.15